HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce maintains a Buy rating on Akero Therapeutics (NASDAQ:AKRO) and raises the price target from $43 to $50.
March 05, 2024 | 11:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Akero Therapeutics and raises the price target from $43 to $50.
The upgrade in the price target from $43 to $50 by a reputable analyst firm like HC Wainwright & Co. suggests a strong confidence in Akero Therapeutics' future performance. This positive analyst action is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100